서브메뉴
검색
Unveiling the Pathogenic Role of B Cells in Metabolic Dysfunction-Associated Steatohepatitis
Unveiling the Pathogenic Role of B Cells in Metabolic Dysfunction-Associated Steatohepatitis
상세정보
- 자료유형
- 학위논문 서양
- 최종처리일시
- 20260202103550
- ISBN
- 9798286445783
- DDC
- 616.079
- 저자명
- Barrow, Fanta.
- 서명/저자
- Unveiling the Pathogenic Role of B Cells in Metabolic Dysfunction-Associated Steatohepatitis
- 발행사항
- [Sl] : University of Minnesota, 2025
- 발행사항
- Ann Arbor : ProQuest Dissertations & Theses, 2025
- 형태사항
- 161 p
- 주기사항
- Source: Dissertations Abstracts International, Volume: 86-12, Section: B.
- 주기사항
- Advisor: Revelo, Xavier.
- 학위논문주기
- Thesis (Ph.D.)--University of Minnesota, 2025.
- 초록/해제
- 요약Metabolic dysfunction-associated steatohepatitis (MASH) is rapidly becoming a leading cause of liver failure and liver transplantation. Characterized by chronic inflammation, liver injury, and fibrosis, untreated MASH can progress to cirrhosis and liver cancer. While hepatic inflammation is a key feature, the immune pathways involved are poorly understood. B cells are adaptive immune cells that produce antibodies, pro- and anti-inflammatory cytokines, and modulate the activation and function of other immune cells. Recently emerging as central mediators of MASH progression, their role in disease is incompletely understood. Using a diet-induced murine model of MASH, this thesis investigates the role of B cells in MASH pathogenesis and uncovers the mechanisms leading to their activation.Using single-cell immune profiling and bulk RNA sequencing, MASH livers were found to accumulate B cells with elevated pro-inflammatory cytokine secretion, antigen presentation, and immunoglobulin production. B-cell activation was driven by a synergy between innate signaling via myeloid differentiation primary response protein 88 (MyD88) and adaptive mechanisms involving B cell-receptor signaling. Deletion of MyD88 in B cells reduced hepatic inflammation and fibrosis, while fecal microbiota transplantation from MASLD patients to lean mice promoted steatosis and B cell activation.To meet the metabolic demands of their activation and effector responses, these B cells rely on oxidative phosphorylation driven selectively by pyruvate oxidation. Genetic deletion or pharmacological inhibition of the mitochondrial pyruvate carrier (MPC) in B cells significantly reduced their inflammatory cytokine and IgG production, ameliorating hepatic steatosis, inflammation, and fibrosis.Using B cell receptor (BCR) sequencing, B cells were found to have reduced clonal expansion but heightened clonal diversity in MASH livers, indicative of polyclonal activation whereby multiple antigens simultaneously stimulated diverse B cell clones. Accordingly, mice engineered to express a transgenic BCR specific to a single irrelevant antigen exhibited suppressed B cell effector responses, reduced T cell- and macrophage-mediated inflammation, and improved hepatic outcomes, highlighting the contribution of polyclonal B cell activation to MASH progression. Mechanistically, this thesis identifies a novel pathway whereby IgG produced by B cells directly activates hepatic stellates driving fibrotic remodeling in MASH.Collectively, these findings position polyclonal B cell activation, pyruvate oxidation, and IgG as central mediators of MASH pathology. By identifying the BCR, Myd88, mitochondrial pyruvate carrier, and MASLD-associated gut microbiota as key regulators of B cell metabolic and inflammatory functions, this thesis provides insights into novel therapeutic targets for treating MASH.
- 일반주제명
- Immunology
- 일반주제명
- Physiology
- 일반주제명
- Cellular biology
- 키워드
- B cells
- 키워드
- Fibrosis
- 키워드
- Inflammation
- 키워드
- Metabolism
- 기타저자
- University of Minnesota Integrative Biology and Physiology
- 기본자료저록
- Dissertations Abstracts International. 86-12B.
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008260126s2025 us c eng d■001000017357718
■00520260202103550
■006m o d
■007cr#unu||||||||
■020 ▼a9798286445783
■035 ▼a(MiAaPQ)AAI32041797
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a616.079
■1001 ▼aBarrow, Fanta.
■24510▼aUnveiling the Pathogenic Role of B Cells in Metabolic Dysfunction-Associated Steatohepatitis
■260 ▼a[Sl]▼bUniversity of Minnesota▼c2025
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2025
■300 ▼a161 p
■500 ▼aSource: Dissertations Abstracts International, Volume: 86-12, Section: B.
■500 ▼aAdvisor: Revelo, Xavier.
■5021 ▼aThesis (Ph.D.)--University of Minnesota, 2025.
■520 ▼aMetabolic dysfunction-associated steatohepatitis (MASH) is rapidly becoming a leading cause of liver failure and liver transplantation. Characterized by chronic inflammation, liver injury, and fibrosis, untreated MASH can progress to cirrhosis and liver cancer. While hepatic inflammation is a key feature, the immune pathways involved are poorly understood. B cells are adaptive immune cells that produce antibodies, pro- and anti-inflammatory cytokines, and modulate the activation and function of other immune cells. Recently emerging as central mediators of MASH progression, their role in disease is incompletely understood. Using a diet-induced murine model of MASH, this thesis investigates the role of B cells in MASH pathogenesis and uncovers the mechanisms leading to their activation.Using single-cell immune profiling and bulk RNA sequencing, MASH livers were found to accumulate B cells with elevated pro-inflammatory cytokine secretion, antigen presentation, and immunoglobulin production. B-cell activation was driven by a synergy between innate signaling via myeloid differentiation primary response protein 88 (MyD88) and adaptive mechanisms involving B cell-receptor signaling. Deletion of MyD88 in B cells reduced hepatic inflammation and fibrosis, while fecal microbiota transplantation from MASLD patients to lean mice promoted steatosis and B cell activation.To meet the metabolic demands of their activation and effector responses, these B cells rely on oxidative phosphorylation driven selectively by pyruvate oxidation. Genetic deletion or pharmacological inhibition of the mitochondrial pyruvate carrier (MPC) in B cells significantly reduced their inflammatory cytokine and IgG production, ameliorating hepatic steatosis, inflammation, and fibrosis.Using B cell receptor (BCR) sequencing, B cells were found to have reduced clonal expansion but heightened clonal diversity in MASH livers, indicative of polyclonal activation whereby multiple antigens simultaneously stimulated diverse B cell clones. Accordingly, mice engineered to express a transgenic BCR specific to a single irrelevant antigen exhibited suppressed B cell effector responses, reduced T cell- and macrophage-mediated inflammation, and improved hepatic outcomes, highlighting the contribution of polyclonal B cell activation to MASH progression. Mechanistically, this thesis identifies a novel pathway whereby IgG produced by B cells directly activates hepatic stellates driving fibrotic remodeling in MASH.Collectively, these findings position polyclonal B cell activation, pyruvate oxidation, and IgG as central mediators of MASH pathology. By identifying the BCR, Myd88, mitochondrial pyruvate carrier, and MASLD-associated gut microbiota as key regulators of B cell metabolic and inflammatory functions, this thesis provides insights into novel therapeutic targets for treating MASH.
■590 ▼aSchool code: 0130.
■650 4▼aImmunology
■650 4▼aPhysiology
■650 4▼aCellular biology
■653 ▼aB cells
■653 ▼aFibrosis
■653 ▼aInflammation
■653 ▼aLiver transplantation
■653 ▼aMetabolic dysfunction-associated steatohepatitis
■653 ▼aMetabolism
■690 ▼a0982
■690 ▼a0719
■690 ▼a0769
■690 ▼a0379
■71020▼aUniversity of Minnesota▼bIntegrative Biology and Physiology.
■7730 ▼tDissertations Abstracts International▼g86-12B.
■790 ▼a0130
■791 ▼aPh.D.
■792 ▼a2025
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17357718▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.


